Novo Unveils $23B Plan to Survive the Ozempic Patent Guillotine (Bagholders Not Waiting 9 Years)
Zuck wasn’t the only loser this weekend…
Novo shares got prescribed a YUGE 5% haircut after the Ozempic maker showed investors its plan for life after the fat-shot gold rush.
Think Michael Scott at the shareholder meeting energy.
Quick history lesson: Novo became one of Europe’s most valuable companies by discovering that Americans will pay almost anything to avoid counting calories.
Then Eli Lilly showed up with Mounjaro and Zepbound, grabbed the majority of the injectable GLP-1 market and ironically put Novo on an involuntary corporate weight-loss plan.
That forced the Ozempic maker to confront a very disturbing question:
“What happens when everyone else copies our homework?”
Novo’s answer arrived Monday during its Capital Markets Day in London, where CEO Mike Doustdar unveiled plans to launch more than five drugs with “multi-blockbuster” potential by 2030.
The company also expects its current pipeline to generate more than 150 billion Danish kroner (or approximately $23 billion) in risk-adjusted sales by 2035.
Investors: “Anything sooner?”
Novo: “Have you considered living another nine years?”
Needless to say, that wasn’t the miracle shareholders were praying for.
At the center of this big pharma soap opera is semaglutide, which made Wegovy and Ozempic household names… and made Novo obscenely rich.
In fact, the drug helped Novo create the modern obesity-treatment market.
Unfortunately, creating a wildly profitable new market is like posting a viral TikTok… within 24 hours, everyone’s copied it with worse lighting.
“We created an incredibly attractive market, and now almost every other single pharma company, big or small, is trying to come and compete with us,” Doustdar said (hands likely shaking from fear).
Worse, semaglutide’s key U.S. patent exclusivity expires in 2032.
That’s unfortunate because America accounted for over half of Novo’s sales last year… and generic manufacturers are already waiting outside with syringes, calculators and absolutely no shame.
Doustdar called the patent cliff “the elephant in the room,” saying the company plans to emerge on the other side as a larger and more diversified drugmaker.
First, however, it must survive getting trampled by the elephant.
But have no fear… Novo’s new plan is to treat damn near everything.
Blood disorders? Sure. Liver disease? Why not? Cardiovascular medicine? Toss it in the cart. And if Novo’s laboratories can’t produce the goods, management is prepared to buy somebody else’s homework.
The problem? Doustdar spent last year telling everyone that focus was the answer.
Snip, snap, snip, snap.
Novo’s Wegovy pill has enjoyed a strong U.S. launch and is beginning to enter additional markets. But it still represents a relatively small portion of total sales, while Lilly has already seized the majority of the injectable GLP-1 market.
Over the previous 12 months, Novo shares had fallen 27% before Monday’s selloff.
Lilly?
Up 52%.
Novo’s big promise? Revenue growth “in line” with pharmaceutical peers through 2030. Investors Bagholders, however, didn’t buy Novo to run alongside the herd. They bought the company that was supposed to trample it.
They bought the company that promised to steamroll the competition.
And down goes Novo. Again.
At the time of publishing this article, Stocks.News doesn’t hold positions in companies mentioned in the article.